Chugai Pharmaceutical Co Ltd
TSE:4519

Watchlist Manager
Chugai Pharmaceutical Co Ltd Logo
Chugai Pharmaceutical Co Ltd
TSE:4519
Watchlist
Price: 6 882 JPY 3.49% Market Closed
Market Cap: 11.6T JPY
Have any thoughts about
Chugai Pharmaceutical Co Ltd?
Write Note

Gross Margin
Chugai Pharmaceutical Co Ltd

70.5%
Current
65%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
70.5%
=
Gross Profit
805.2B
/
Revenue
1.1T

Gross Margin Across Competitors

Country JP
Market Cap 11.3T JPY
Gross Margin
70%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 756.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 349.7B USD
Gross Margin
69%
Country US
Market Cap 251.6B USD
Gross Margin
77%
Country CH
Market Cap 199.5B CHF
Gross Margin
73%
Country UK
Market Cap 161.6B GBP
Gross Margin
82%
Country CH
Market Cap 171.3B CHF
Gross Margin
75%
Country US
Market Cap 151.4B USD
Gross Margin
71%
No Stocks Found

Chugai Pharmaceutical Co Ltd
Glance View

Market Cap
11.3T JPY
Industry
Pharmaceuticals
Economic Moat
Narrow

Chugai Pharmaceutical Co., Ltd., a pivotal player in the pharmaceutical industry, finds its roots deeply intertwined with innovations in biotechnology. Established in Tokyo, Chugai has carved out a niche by focusing on the development and distribution of prescription pharmaceuticals tailored to address some of the most challenging medical conditions. The company's collaboration with Roche, a global healthcare leader, has strategically positioned it within the Roche Group, allowing access to an expansive trove of research and development resources. This partnership amplifies Chugai's innovative efforts, particularly in biologics and oncology, where they develop antibodies and therapies that have been instrumental in advancing clinical treatments worldwide. The synergy of Chugai's science-driven approach, coupled with Roche's global reach, has fostered a dynamic research environment that continues to push the boundaries of medical treatment possibilities. Revenue streams for Chugai are primarily anchored in the research, development, and subsequent commercialization of novel pharmaceuticals. The company gains its financial strength through successful product launches, sustained sales of flagship products, and collaborative research agreements. Chugai's extensive pipeline, particularly in the fields of oncology, immunology, and renal diseases, reflects a strategic emphasis on addressing unmet medical needs, with a considerable portion of their earnings reinvested into further research. Additionally, strategically negotiated licensing agreements allow Chugai to bolster its financial health by sharing its innovations with other industry players, maximizing distribution channels while ensuring a steady cash influx. Through this intricate balance of innovation, strategic partnerships, and a robust commercial network, Chugai not only thrives within the competitive pharmaceutical landscape but also contributes significantly to the global healthcare ecosystem.

Intrinsic Value
4 526.93 JPY
Overvaluation 34%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
70.5%
=
Gross Profit
805.2B
/
Revenue
1.1T
What is the Gross Margin of Chugai Pharmaceutical Co Ltd?

Based on Chugai Pharmaceutical Co Ltd's most recent financial statements, the company has Gross Margin of 70.5%.